Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | FABP4 | P15090 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 1/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6637612 | 0.88 | TAS2R14 (0.42) | TAS2R14S1PR1TACR1PLK1ACLY | |
| SCHEMBL8070699 | 0.88 | TAS2R14 (0.47) | TAS2R14S1PR1RXRARXRBFABP4 | |
| SCHEMBL6636502 | 0.85 | CFTR (0.47) | TAS2R14S1PR1PLK1NOTUMLDHA | |
| SCHEMBL6500060 | 0.81 | ALDH1A1 (0.51) | FABP4FOLH1LDHAPTPN1MCL1 | |
| SCHEMBL6639868 | 0.81 | PRKAB2 (0.44) | FABP4NOTUMFOLH1PTPN1 | |
| SCHEMBL27968054 | 0.81 | ACLY (0.47) | TAS2R14RXRARXRBFABP4PLK1 | |
| SCHEMBL6637281 | 0.80 | HSP90AA1 (0.49) | S1PR1TACR1FABP4PLK1FOLH1 | |
| SCHEMBL27532813 | 0.80 | LDHA (0.53) | FABP4FOLH1LDHAPTPN1MCL1 | |
| SCHEMBL27910049 | 0.80 | S1PR1 (0.44) | TAS2R14S1PR1TACR1PLK1ACLY | |
| SCHEMBL6683660 | 0.78 | S1PR1 (0.48) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1472226-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-03 | — | — | EP | disclosed |
| US-20040044008-A1 | Use of therapeutic benzamide derivatives | DAUGAN ALAIN CLAUDE-MARIE (FR) | 2004-03-04 | — | — | US | disclosed |
| WO-2003045921-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044008-A1 | Use of therapeutic benzamide derivatives | MTTP, LIPC, CETP | TAS2R14 1864/4885S1PR1 2716/4885RXRA 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.